[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hpylori-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hpylori-infection":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,40,72,95,117],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100568538","tegoprazan--versus-ppi-based-h-pylori-eradication-100568538",false,"NCT06682533","Tegoprazan- Versus PPI-based H. Pylori Eradication","Efficacy and Tolerability of 14-Day Tegoprazan-based Triple Therapy for Eradication of Helicobacter Pylori Eradication: A Retrospective Study","Inclusion Criteria:\n\n* Gastroscopy can be performed\n* H. pylori test and pathological analysis can be performed\n\nExclusion Criteria:\n\n* Age \\\u003C 20 or \\> 80 years\n* Anemia (serum hemoglobin level \\\u003C 10 g\u002FdL)\n* Severe systemic disease\n* Advanced chronic liver disease\n* Use of certain medications, including proton pump inhibitors, H2- receptor antagonists, or antibiotics\n* History of H. pylori eradication\n* Drug allergy to antibiotics\n* History of gastric surgery\n* Recent history of upper gastrointestinal bleeding","ALL","20 Years","80 Years",{"count":20,"type":21},200,"ESTIMATED","1 Year","OBSERVATIONAL","In 2015, vonoprazan, a potassium-competitive blocker (P-CAB), was launched in Japan and used as an alternative for proton pump inhibitors (PPIs) for eradicating Helicobacter pylori. In recent studies, vonoprazan-based triple therapy significantly increased the eradication rate from 72.8% to 87.9%, compared to PPI treatment group. Accordingly, the Japanese Helicobacter treatment guidelines recommend prescribing P-CAB for eradication treatment. In 2018, a new P-CAB, tegoprazan, was developed in Korea and approved for gastric ulcer treatment. Subsequently, it was proven effective in the treatment of reflux esophagitis compared to PPIs in a non-inferiority clinical trial. P-CAB can increase the gastric pH to 6 or higher within 7 hours after taking tegoprazan. Because tegoprazan can be taken after meals, it can improve patient compliance for H. pylori eradication. Unlike vonoprazan in Japan, however, tegoprazan-based eradication in Korean population was similar to conventional PPI-based treatment. To date, the eradication success rates of PPI and tegoprazan-based triple therapy were 76.4-84.2% and 77.3-84.3%, respectively, and there was no significant difference between the two treatment groups.\n\nBismuth has long been used as a semi-metal in the dyspepsia and traveler's diarrhea. In H. pylori eradication therapy, several guidelines recommended the addition of bismuth to treatment regimens. Recently, bismuth was added to the 2-week triple regimen to increase the first-line H. pylori eradication rate in countries with high antibiotic resistance. The H. pylori eradication significantly increased from 87.5-88.1% to 95.8-97.3% in a recent study. The odds ratio was 1.63-2.18 in bismuth-added treatment group, compared to no use of bismuth group. In subgroup analysis, odd ratio was 1.66-2.22 in high clarithromycin-resistant areas. However, there was no comparative analysis of PPIs and tegoprazan in a bismuth-added triple therapy.",[26],"H.Pylori Infection","RECRUITING","2026-04-21",{"date":30,"type":31},"2026-04-23","ACTUAL",{"date":33,"type":31},"2024-12-01",{"date":35,"type":21},"2026-12-31",{"name":37,"class":38},"Soonchunhyang University Hospital","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":39},"100619429","phase-4-cure-h-pylori-a-trial-on-the-combination-of-anti-ulcerants-and-levofloxacin-based-therapy-for-helicobacter-pylori-eradication-100619429","NCT07344506","CURE-H. Pylori: A Trial on the Combination of Anti-Ulcerants and Levofloxacin-Based Therapy for Helicobacter Pylori Eradication","Evaluating the Effectiveness of Anti- Ulcerants (Dexlansoprazole, Lansoprazole, and Vonoprazan) With Levofloxacin-based Triple Therapy for Helicobacter Pylori Eradication - A Three-arm Randomized Controlled Trial","CURE-H Pylori","Inclusion Criteria:\n\nAdult patients of both sexes, presenting to the out-patient departments of the participating healthcare centres, and diagnosed through a UBT to have H.Pylori infection by their physician will be eligible for enrolment in the study, but are currently not receiving any treatment for H.Pylori infection.\n\nExclusion Criteria:\n\n1. Those who will not provide written consent for the study.\n2. Patients with severe mental disability,\n3. pregnant or lactating women,\n4. those who are already on treatment for H.Pylori infection, and\n5. those who have received any antibiotic within the last two weeks of enrolling in this study will be excluded.\n6. Patients with known previous documented drug allergies for the current regime will be excluded from the trial",true,"18 Years",{"count":51,"type":21},942,"INTERVENTIONAL",[54],"PHASE4","This study, titled CURE-H. Pylori, is a three-arm, parallel-group, open-label, randomized controlled trial designed to evaluate the effectiveness of Dexlansoprazole, Lansoprazole, and Vonoprazan in combination with Levofloxacin and Amoxicillin for Helicobacter pylori eradication. H. pylori infection is a significant health issue worldwide, with an estimated prevalence of 44% globally and around 60% in Pakistan, leading to gastritis, peptic ulcer disease, and increased risks of gastric cancer and mucosa-associated lymphoid tissue lymphoma. Despite the widespread use of PPI-based triple therapies, treatment efficacy has decreased due to increasing antibiotic resistance, especially to Clarithromycin and Metronidazole. This study aims to assess the eradication rate of H. pylori in patients receiving either Dexlansoprazole 60mg, Lansoprazole 30mg, or Vonoprazan 20mg, each combined with Levofloxacin 500mg and Amoxicillin 1g for 14 days. Participants will be randomized into three arms (314 participants per arm) and assessed for H. pylori eradication using a Urea Breath Test (UBT) at follow-up, which will serve as the primary endpoint. Secondary objectives include assessing symptom improvement using the Gastrointestinal Symptom Rating Scale (GSRS), measuring symptoms such as reflux, abdominal pain, indigestion, diarrhea, and constipation. The study will enroll adult patients diagnosed with H. pylori via UBT and who are not currently receiving treatment for the infection. The study will be conducted at healthcare centers in major cities across Pakistan, including Peshawar, Faisalabad, Rawalpindi, Multan, Lahore, Karachi, and Quetta, over a 12-month period. All participants will sign informed consent forms before enrollment, ensuring they understand the study's procedures and risks. Statistical analysis will be performed using SPSS version 26, with categorical variables analyzed using the Chi-square or Fisher's exact test and continuous variables using descriptive statistics. The primary outcome is the H. pylori eradication rate, and secondary outcomes include the improvement in gastrointestinal symptoms. This study is significant because it aims to compare three different PPI-based therapies in the context of H. pylori eradication in a high-resistance population, providing much-needed data for tailoring treatment strategies in regions with high antibiotic resistance like Pakistan. The results could enhance the effectiveness and cost-efficiency of treatment regimens for H. pylori, ultimately improving patient outcomes and reducing the burden of gastric diseases. Ethical approval has been obtained from the Institutional Review Board (IRB) of Dow University of Health Sciences, Karachi, and all procedures will adhere to the principles of human subjects protection. This study will provide valuable insights into the comparative efficacy of different proton pump inhibitors when combined with Levofloxacin-based triple therapy, potentially leading to more effective treatment options for H. pylori infections in Pakistan and similar regions. The total required sample size for this study is 942 participants, with a 20% expected dropout rate. Data collection will be conducted at baseline and six weeks post-treatment, with the aim of addressing the region-specific challenges in H. pylori treatment and contributing to the global knowledge on optimal therapeutic strategies for this infection. Additionally, the trial's findings may contribute to the broader understanding of how regional antibiotic resistance patterns affect treatment outcomes and help shape future guidelines for H. pylori management in endemic areas. This trial will also help assess the safety and tolerability of the different therapies, providing a comprehensive evaluation of both therapeutic efficacy and patient quality of life post-treatment.",[57,26,58],"H. Pylori Gastrointestinal Disease","H.Pylori Eradication Rate",[60,61,62],"Helicobacter pylori, Peptic ulcer disease, Combination Triple regime, Dexlansoprazole, Lansoprazole, Vonoprazan, Eradication therapy, Treatment Efficacy","Randomized Controlled Trial","Three Arm","2026-01-07",{"date":65,"type":31},"2026-01-15",{"date":67,"type":31},"2025-05-01",{"date":69,"type":21},"2026-08-01",{"name":71,"class":38},"Dow University of Health Sciences",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":4},"100614804","barriers-of-general-practitioner-regarding-helicobacter-pylori-100614804","NCT07284355","Barriers of General Practitioner Regarding Helicobacter Pylori.","Knowledge, Attitude, Practices and Barriersof General Practitioner RegardingHelicobacter Pylori Diagnosis andTreatment","Inclusion Criteria:\n\n\\- Licensed general practitioners actively working primary health care centers, outpatients clinics and general hospitals in Upper Egypt( Assuit, Minya, Sohag, Qena, luxor and Aswan).\n\nExclusion Criteria:\n\n* Specialists in gastroenterology.",{"count":80,"type":21},300,"This study aims to evaluate the knowledge, attitudes, and clinical practices of general practitioners regarding the diagnosis and treatment of Helicobacter pylori infection. The study also seeks to identify the main barriers that prevent proper management of the condition. The central hypothesis is that gaps in knowledge and challenges in clinical practice contribute to variations in how general practitioners diagnose and treat H. pylori infection.",[26],[84],"H.pylori infection","NOT_YET_RECRUITING","2025-12-07",{"date":88,"type":31},"2025-12-16",{"date":90,"type":21},"2025-12-15",{"date":92,"type":21},"2026-12-15",{"name":94,"class":38},"Assiut University",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":48,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":52,"phases":103,"briefSummary":105,"conditions":106,"keywords":107,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":4},"100548776","intrafamilial-helicobacter-pylori-infection-in-hong-kong-100548776","NCT06425393","Intrafamilial Helicobacter Pylori Infection in Hong Kong","Prevalence and Risk Factors of Intrafamilial Helicobacter Pylori Infection in Hong Kong: a Prospective Cohort Study","Inclusion Criteria:\n\n* Adults age\\>=18 years of age\n* For H. pylori infected patients only: Diagnosed to have H. pylori infection by either histology, rapid urease test or urea breath test\n* Written informed consent obtained\n\nExclusion Criteria:\n\n* Unable to perform urea breath test\n* Contraindications for urea breath test\n* Used antibiotics within the past month\u002Fproton pump inhibitors within two weeks",{"count":80,"type":21},[104],"NA","It is a single-centre, prospective cohort study, which will be conducted in a tertiary academic hospital. The study aims to investigate intrafamilial H. pylori infection status and to identify risk factors for H. pylori infection among household members.\n\nThe rate of intrafamilial H. pylori spread in Hong Kong is currently unknown. It is also not clear whether the same risk factors for intrafamilial spread of H. pylori infection also apply in Hong Kong. In contrast to mainland China and Taiwan , recent consensus guideline on H. pylori management in Hong Kong in 2023 recommends against routine testing of asymptomatic household members or family members of H. pylori-infected adults. There is a knowledge gap on whether the family-based H. pylori screening is cost effective in our locality. Thus, the investigator aim to investigate infection status of household members of H. pylori infected individuals and risk factors for household infection in Hong Kong. The result from this study will shed light on the role of family-based screening and can inform future healthcare policy making on the strategy of H. pylori management and treatment in Hong Kong, ameliorating H. pylori infection-related disease and gastric cancer burden for society.",[26],[84],"2024-05-20",{"date":110,"type":31},"2024-05-22",{"date":112,"type":21},"2024-06-11",{"date":114,"type":21},"2026-12-10",{"name":116,"class":38},"Chinese University of Hong Kong",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":126,"conditions":127,"keywords":131,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":5},"100364198","screening-of-gastric-cancer-via-breath-volatile-organic-compounds-by-hybrid-sensing-approach-100364198","NCT04022109","Screening of Gastric Cancer Via Breath Volatile Organic Compounds by Hybrid Sensing Approach","VOGAS","Inclusion Criteria:\n\n* Patients with verified gastric cancer (Group 1 \\& 2)\n* Patients undergoing or having undergone upper endoscopy according to clinical indications (Group 3 \\& 5)\n* Average-risk population group aged 40-64 at inclusion without alarm symptoms (Group 4)\n* Motivation to participate in the study\n* Physical status allowing volatile marker sampling and other procedures within the protocol\n* Signed consent\n\nExclusion Criteria:\n\n* Known other active cancer\n* Ventilation problems, airway obstruction\n* Unwillingness or inability to co-operate",{"count":125,"type":21},5000,"The study is aimed to determine the potential of volatile marker testing for gastric cancer screening.\n\nThe study will be addressing the role of confounding factors, including lifestyle factors, diet, smoking as well as addressing the potential role of microbiota in the composition of exhaled volatile markers.",[128,129,130,26],"Gastric Cancer","Atrophic Gastritis","Gastric Dysplasia",[132,133,134,135,136,137,138,139],"Volatile organic compounds","Breath testing","Gastric cancer","Atrophic gastritis","Precancerous lesions","Screening","Nanosensor technology","GC-MS","2021-07-19",{"date":142,"type":31},"2021-07-26",{"date":144,"type":31},"2019-11-01",{"date":146,"type":21},"2026-12",{"name":148,"class":38},"University of Latvia"]